As you guyz are the veteran, I would like your input. Answers from other posters are also welcome as long as they are not derogatory. Last time when OGXI presented phase 2 data in May 2009 at ASCO annual conference, the SP shot from around 6 to 35. OGX-427 is to be presented Asco GU 2012 for prostate cancer.I know its not a big conference as ASCO annual conf, but do you guyz expect to see any meaningful data n corresponding bump in SP? Also the trial is evaluating disease free survival at 12 weeks, will they present the OS data also ? The 10 Q filing only says interim data to be presented at Asco GU 2012 but it doesn't say what parameters will be presented.
Hi Herman. pps shot up in summer 2009 due to results at ASCO and anticipation of buyout in light of Cougar buyout from J and J. If 427 results are very good, I think we may see $20. there will not be a repeat of the summer of 2009 because no chance of buyout of OGXI in light of TEVA joint venture on 011.
I will look at some analyst reports to see the data to be released at ASCO in February. 427 shrinks tumours. Will the "shrinkage factor" be released or OS data be released? Can OS be extrapolated from tumour shrinkage?
I will check, but others on this board know the science better than I do.